Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Leveraging AS01-induced immune cell reprogramming to modulate immune dysregulation in rheumatoid ... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase I/II open label study of DJI136, a DLL3-targeted CAR-T therapy, in adult patients with ES... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Beamion PANTUMOR 1: A Phase II, multicentre, multicohort, open-label trial to evaluate the effica... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLOZASIRAN... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Inves... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo i... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Safety, immunogenicity and efficacy of low dose Nivolumab in adults living with HIV on antiretrov... Read More